Serious complications after smallpox and Mpox vaccines
The US government report shows serious complications after usage of ACAM2000 Smallpox and Mpox vaccine including dead of unvaccinated individuals who have contact with vaccinated individuals.
Other warnings and precautions:
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000 or other live vaccinia virus vaccines that were used historically. These risks are increased in certain individuals and may result in severe disability, permanent neurological sequelae and/or death.
Adverse reactions:
Common adverse reactions include inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache (6). These adverse reactions are less frequent in revaccinated persons than persons receiving the vaccine for the first time. Inadvertent inoculation at other sites is the most frequent complication of vaccinia vaccination. The most common sites involved are the face, nose, mouth, lips, genitalia and anus. Self-limited skin rashes not associated with vaccinia replication in skin, including urticaria and folliculitis, may occur following vaccination.
Vaccine recipients or caregivers must be advised that virus is shed from the cutaneous lesion at the site of inoculation from approximately Day 2 post-vaccination until the scab separates and the lesion is reepithelialized typically 3 to 6 weeks after primary vaccination. Vaccinia virus may be transmitted by direct physical contact.
The following information regarding the safety of ACAM2000 was derived from three sources: 1) ACAM2000 clinical trial experience (Phase 1, 2 and 3 clinical trials), 2) data compiled during the era of routine smallpox vaccination using other New York City Board of Health (NYCBH) vaccinia vaccines and 3) adverse event data obtained during military and civilian smallpox vaccination programs (2002-2005) that used Dryvax, a formerly licensed live vaccinia virus smallpox vaccine
https://www.fda.gov/media/75792/download?attachment
ACAM2000 is manufactured by an American multinational company Emergent BioSolutions Inc. Top institutional holder are Vanguard Group Inc., American Century Companies Inc, State Street Corporation and Blackrock Inc.
https://finance.yahoo.com/quote/EBS/holders/
The ACAM2000® vaccine has been authorized for use by Health Canada for active immunization against smallpox disease for persons 16 years of age and older determined to be at high risk for smallpox infection.
As a Canadian physician Dr. William Makis, expert in Nuclear Medicine Radiology and Oncology, in his report said: “So, stop taking the injections, no mRNA vaccines, no Covid vaccines, no flu vaccines, childhood vaccines, you should probably avoid all together. We need a complete reset of the entire area of vaccines; we got to scrab the vaccine schedule, the childhood vaccines schedule, start from scratch now, we need a complete reset in medicine and science, get the corruption out first. “
DB
